Pacira BioSciences (PCRX) CFO exercises options and sells 12,941 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Pacira BioSciences Chief Financial Officer Shawn Cross reported option-related transactions in company common stock. On April 23, 2026, he exercised stock options to acquire 12,941 shares at $16.45 per share and sold 12,941 shares in open-market trades at a weighted average price of $25.16, within a range of $25.00 to $25.41. The filing shows these moves were made under a pre-established Rule 10b5-1 trading plan. After the transactions, he directly owned 105,341 shares of Pacira common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 12,941 shares ($325,596)
Net Sell
3 txns
Insider
Cross Shawn
Role
Chief Financial Officer
Sold
12,941 shs ($326K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 12,941 | $0.00 | -- |
| Exercise | Common Stock | 12,941 | $16.45 | $213K |
| Sale | Common Stock | 12,941 | $25.16 | $326K |
Holdings After Transaction:
Stock Option (Right to Buy) — 150,000 shares (Direct, null);
Common Stock — 118,282 shares (Direct, null)
Footnotes (1)
- The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on June 9, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.41, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.
Key Figures
Shares sold: 12,941 shares
Sale price (weighted average): $25.16 per share
Sale price range: $25.00–$25.41 per share
+5 more
8 metrics
Shares sold
12,941 shares
Common stock sold in open-market transactions on April 23, 2026
Sale price (weighted average)
$25.16 per share
Weighted average price for 12,941 shares sold
Sale price range
$25.00–$25.41 per share
Price range of individual sale transactions
Options exercised
12,941 shares
Common shares acquired via option exercise on April 23, 2026
Option exercise price
$16.45 per share
Exercise price of stock option for 12,941 shares
Post-transaction holdings
105,341 shares
Common shares directly owned by CFO after transactions
Option expiration
November 4, 2034
Expiration date of the stock option exercised
Net buy/sell shares
12,941 shares net sell
Net share change from reported transactions
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vested and became exercisable, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"were effected pursuant to a Rule 10b5-1 trading plan previously adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vested and became exercisable financial
"The stock option vested and became exercisable as to 25% of the option shares"
continuous service other
"over the subsequent three years, provided that the reporting person remains in continuous service"
FAQ
What did Pacira BioSciences (PCRX) CFO Shawn Cross report in this Form 4?
Pacira CFO Shawn Cross reported an option exercise and related stock sale. He exercised options for 12,941 common shares and sold 12,941 shares in open-market transactions, all carried out under a pre-established Rule 10b5-1 trading plan.
At what price did the Pacira (PCRX) CFO exercise his stock options?
He exercised stock options covering 12,941 shares at an exercise price of $16.45 per share. These options were part of a grant that vested over time, contingent on his continued service with Pacira BioSciences.
Were the Pacira (PCRX) CFO’s trades made under a Rule 10b5-1 plan?
Yes. The Form 4 states that both the option exercise and stock sales were executed under a Rule 10b5-1 trading plan. This plan was previously adopted by Shawn Cross in accordance with Rule 10b5-1 of the Securities Exchange Act.
What does the vesting footnote say about the Pacira (PCRX) CFO’s stock options?
The stock option vested 25% of the shares on the first anniversary of the grant date, with the remainder vesting in equal quarterly installments over the next three years, conditioned on Shawn Cross’s continuous service with Pacira.